Takeda presents positive results from trial of chronic kidney disease treatment
Ella Day | June 10, 2025 | News story | Research and Development |Â Â European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney diseaseÂ
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A nephropathy (IgAN), a chronic kidney disease. The Japanese biopharma is now looking ahead to a prospective phase 3 trial of mezagitamab.
The data was presented at the European Renal Association Congress on 6 June 2025 in Vienna, Austria. It indicated that at week 48, IgAN patients treated with mezagitamab experienced significant benefits compared to those who received standard-of-care therapy alone. These patients achieved rapid and sustained reductions in both serum IgA and proteinuria, as well as stable renal function. Additionally, no serious adverse side effects or discontinuations were reported.
IgAN is a common autoimmune disease often diagnosed in young people (aged approximately 10 to 30 years) and is characterised by the production of abnormally formed IgA. The condition causes progressive and irreversible damage to kidney function, with around 30% of patients losing kidney function entirely, requiring a kidney transplant or life on dialysis.
Mezagitamab is a human anti-CD38 monoclonal antibody that depletes the plasma cells that produce galactose-deficient IgA1 (Gd-IgA1) and autoantibodies against GdIgA1. This intends to reduce immune complex formation, proteinuria and promote stabilisation of kidney function over time.
Ella Day
10/6/25
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in …
